Setmelanotide Shows Promise in Hypothalamic Obesity

Setmelanotide treatment was found to lead to a consistent decrease in bodyweight and hunger in patients with hypothalamic obesity over a 16-week period. The study, published in The Lancet Diabetes & Endocrinology, included 18 participants who received setmelanotide and showed significant reductions in BMI, bodyweight, and waist circumference. The treatment was generally well-tolerated, with common side effects including nausea, vomiting, and skin hyperpigmentation. The study suggests that impaired melanocortin signaling may play a role in the pathophysiology of hypothalamic obesity. However, the study had limitations such as its small size and lack of control group.

Source link

error: Content is protected !!